Genitourinary Cancers | Matthew R Smith, MD, PhD - a podcast by Dr Neil Love
from 2019-06-03T21:07:42
::
::
Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Prostate Cancer — Part 2: Our one-on-one interview with Dr Smith featuring emerging research and cases from his practice.
- Recent advances in the treatment of nonmetastatic CRPC (00:00)
- Effect of PSA doubling time on prognosis for patients with nonmetastatic disease (3:01)
- PSA doubling time and clinical decision-making for patients with M0 disease (7:59)
- Counseling patients with nonmetastatic disease about goals of therapy and expected side effects (10:26)
- Similarities and differences in the design, entry criteria and efficacy endpoints among the ARAMIS, SPARTAN and PROSPER trials (13:25)
- Comparison of the side-effect profiles of apalutamide, enzalutamide and darolutamide (15:35)
- Counseling patients receiving long-term ADT about treatment-related fatigue (18:35)
- Comparison of primary (metastasis-free survival) and secondary outcomes among the ARAMIS, SPARTAN and PROSPER trials (20:32)
- Choosing among darolutamide, apalutamide and enzalutamide (22:45)
- SPARTAN trial: PFS2 improvement with apalutamide for high-risk nonmetastatic CRPC (24:42)
- Outcomes, tolerability and appropriate use of abiraterone in combination with prednisone (26:27)
- Similarities and differences in the design, entry criteria and efficacy endpoints between the LATITUDE (ADT with abiraterone/prednisone or placebo) and ARCHES (ADT with enzalutamide or placebo) trials for patients with metastatic HSPC (29:46)
- Key clinical and practical factors guiding the selection of docetaxel versus abiraterone/prednisone for metastatic HSPC (35:39)
- Perspective on the intensification of therapy for patients with metastatic HSPC and suboptimal responses to ADT (39:08)
- Spectrum and frequency of somatic and germline DNA repair gene mutations in prostate cancer; activity of PARP inhibitors in patients with metastatic CRPC (40:57)
- Incidence of MSI-H/dMMR molecular phenotype in patients with prostate cancer; indications for testing and current role of immune checkpoint inhibitors (46:37)
- Results of a Phase II prospective trial of lutetium-177-PSMA-617 theranostics in metastatic CRPC (50:42)
- Novel immune checkpoint inhibitor-based combinations for metastatic CRPC (56:08)
Further episodes of Research To Practice | Oncology Videos
Further podcasts by Dr Neil Love
Website of Dr Neil Love